544 related articles for article (PubMed ID: 30414440)
1. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
Pelaia G; Gallelli L; Romeo P; Renda T; Busceti MT; Proietto A; Grembiale RD; Marsico SA; Maselli R; Vatrella A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
[TBL] [Abstract][Full Text] [Related]
3. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
4. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
5. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
6. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
7. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
8. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
[TBL] [Abstract][Full Text] [Related]
9. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
10. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study.
Solidoro P; Patrucco F; de Blasio F; Brussino L; Bellocchia M; Dassetto D; Pivetta E; Riccio A; Heffler E; Canonica W; Rolla G; Bucca C
Ther Adv Respir Dis; 2019; 13():1753466619841274. PubMed ID: 31002021
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
13. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
14. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
18. Response to omalizumab in patients with severe allergic asthma: A real-life study.
Zierau L; Walsted ES; Thomsen SF; Backer V
Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
[TBL] [Abstract][Full Text] [Related]
19. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
[TBL] [Abstract][Full Text] [Related]
20. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]